Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

55.96USD
2 Dec 2016
Change (% chg)

$0.16 (+0.29%)
Prev Close
$55.80
Open
$55.71
Day's High
$56.10
Day's Low
$55.32
Volume
2,746,073
Avg. Vol
3,149,547
52-wk High
$77.10
52-wk Low
$49.03

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb- U.S., EU regulators accept application to expand approval for cancer drug, Opdivo
Monday, 18 Jul 2016 06:59am EDT 

Bristol-Myers Squibb Co: Bristol-Myers Squibb announces regulatory updates for Opdivo (nivolumab) in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck .Myers Squibb Co - projected FDA action date is November 11, 2016 for Opdivo.  Full Article

Bristol-Myers acquires Cormorant Pharmaceuticals
Tuesday, 5 Jul 2016 06:59am EDT 

Bristol : Myers Squibb acquires Cormorant Pharmaceuticals . Myers Squibb Co - transaction includes upfront and near term contingent milestone payments of up to us $95 million . Myers Squibb co - company gains full-rights to cormorant's humax-il8 antibody program and lead asset humax-il8 in phase 1/2 development . Myers Squibb co - transaction includes upfront and near term contingent milestone payments of up to us $95 million . Myers Squibb co - transaction has been approved by boards of directors of both companies and by stockholders of cormorant .Myers Squibb co - transaction includes additional contingent consideration of up to us $425 million upon achievement by co of certain milestones.  Full Article

Medadvisor collaborates with Australian unit of Bristol Myers Squibb to patient engagement program
Thursday, 30 Jun 2016 06:41pm EDT 

Medadvisor Ltd : Major biopharmaceutical signs to patient engagement program . Will be collaborating with the Australian subsidiary of Bristol Myers Squibb Company . Says collaborating to deliver a new patient engagement and education program .Says agreement will generate further patient engagement program revenue for Medadvisor.  Full Article

Bristol-Myers Squibb, Psioxus Therapeutics announce immuno-oncology clinical collaboration
Thursday, 30 Jun 2016 06:59am EDT 

Bristol-myers Squibb Co : Bristol-Myers squibb and psioxus therapeutics announce immuno-oncology clinical collaboration to evaluate the combination of opdivo and enadenotucirev . Myers Squibb co says under terms of this agreement, bristol-myers squibb will make a one-time upfront payment of $10 million to psioxus . Myers Squibb Co - bristol-myers squibb will make a one-time upfront payment of $10 million to psioxus, and parties will share development costs . Says Psioxus will be responsible for conducting phase 1 study with patient recruitment expected to start in q3 of 2016 . Bristol-Myers squibb will have a time-limited right of exclusive negotiation for commercial rights to enadenotucirev . Myers - both Co's also investigating other immune system pathways in treatment of cancer including ctla-4, cd-137, kir, slamf7, pd-1, gitr, csf1r, ido and lag-3 .Myers Squibb - Co's will work exclusively with each other on anti-pd-1/pd-l1 antagonist antibody and enadenotucirev combination regimens.  Full Article

Bristol-Myers Squibb's Opdivo gets breakthrough therapy approval from FDA
Monday, 27 Jun 2016 06:59am EDT 

Bristol Myers Squibb Co : Bristol Myers Squibb Co - intends to file marketing application with health authorities based on results from phase 2 study ca209-275, other data . Bristol Myers Squibb - to file marketing application with health authorities based on results from study -275 and other supporting data in coming months .Bristol Myers Squibb's Opdivo (nivolumab) receives breakthrough therapy designation from U.S. Food and drug administration for advanced form of bladder cancer.  Full Article

PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb’s first collaboration product candidate
Wednesday, 15 Jun 2016 02:48am EDT 

PeptiDream Inc <4587.T>: Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS) . Says this is the first program to enter clinical testing out of the discovery collaboration between the two companies .Says the molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization.  Full Article

Bristol-Myers announces phase 2 data for Opdivo studies
Friday, 10 Jun 2016 02:30am EDT 

Bristol-Myers Squibb Co : Says Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients . Says primary endpoint of objective response rate (orr) per an independent radiologic review committee (irrc) was 66.3% . Says safety profile of Opdivo in checkmate -205 was consistent with previously reported data in this tumor type .Says Opdivo indicates benefit in heavily pre-treated classical Hodgkin lymphoma patients in phase 2, single-arm pivotal trial.  Full Article

Bristol-Myers Squibb declares qtrly dividend of $0.38/shr
Tuesday, 7 Jun 2016 04:15pm EDT 

Bristol-Myers Squibb Co :Declared a quarterly dividend of $0.38 per share on $0.10 par value common stock of corporation.  Full Article

Bristol-Myers Squibb, MD Anderson announce new collaboration focused on lung cancer
Tuesday, 7 Jun 2016 06:59am EDT 

Bristol-Myers Squibb Co : Bristol-Myers Squibb and MD Anderson announce new research collaboration in immuno-oncology focused on lung cancer .Bristol-Myers Squibb - collaboration to support Phase 1 and 2 clinical trials testing Opdivo as monotherapy, in combination with Yervoy, or with other agents.  Full Article

Bristol-Myers Squibb presents two-year overall survival data on Opdivo
Wednesday, 18 May 2016 05:40pm EDT 

Bristol-myers Squibb Co : Two-Year overall survival data from two pivotal opdivo® (nivolumab) trials demonstrate sustained benefit in patients with advanced non-small cell lung cancer .Treatment-Related adverse events occurred in 71% and 61% of opdivo -treated patients.  Full Article

BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin